BOTHELL, Wash., April 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , a clinical-stage biopharmaceutical company, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.  In connection with this offering, Alder expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock.

J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. 

A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015.  A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at syndicate@leerink.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at cmclientsupport@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contacts:

David Schull or Lena Evans
Russo Partners
(212) 845-4271  
(212) 845-4262  
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

Investor Relations Contacts:

David Walsey
Alder BioPharmaceuticals, Inc.
(425) 408-8032
dwalsey@alderbio.com